CompletedNot Applicable

Influence of Lipid Lowering on Impaired Coronary Flow

Denmark109 participantsStarted 2020-05-15

Plain-language summary

This study assess in patients with stable chest pain and coronary artery disease (CAD) determined by coronary CTA whether cholesterol lowering with regression of coronary adverse plaque characteristics is associated with recovery of impaired flow

Who can participate

Age range35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥35 y * Symptoms suggestive of stable CAD * No pre-CTA known CAD * At least one lesion with FFRct \<0.81 * Sinus rhythm * LDL cholesterol \>2.0 mM * Statin use \>2 months * Life expentancy \< 3 years * Signed informed consent Exclusion Criteria: * Known CAD * Poor CTA image quality inadequiate for FFRct analysis (determined by corelab) * Significant CAD in the left main or proximal coronary segments * Referral to invasive catheterization * Statin intolerance * BMI \>40 * Allergy to ionidated contrast * Pregnancy

What they're measuring

Changes in FFRct values

Timeframe: 18 months

Trial details

NCT IDNCT05368545

SponsorAarhus University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-17

View on ClinicalTrials.gov More Coronary Artery Disease trials